Do you recommend transitioning from ticagrelor-aspirin DAPT to ticagrelor monotherapy after 1 month in patients with acute coronary syndrome and average bleeding risk post-PCI to reduce the risk of bleeding?

Ge et al. ULTIMATE-DAPT Trial, PMID 38599220 Would your recommendations change if this was 1 month post-PCI for a non-ACS presentation?